Ameriprise Financial Inc Sage Therapeutics, Inc. Transaction History

Ameriprise Financial Inc

$358 Billion
Q1 2024

A detailed history of Ameriprise Financial Inc transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Ameriprise Financial Inc holds 359,535 shares of SAGE stock, worth $3.82 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

359,535

Previous 308,735 16.45%

Holding current value

$3.82 Million

Previous $6.69 Million 0.7%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$18.62 - $26.95 $945,896 - $1.37 Million	50,800 Added 16.45%	359,535 $6.74 Million
Q4 2023 Feb 14, 2024	SELL	$17.1 - $22.26 $6.9 Million - $8.99 Million	-403,689 Reduced 56.66%	308,735 $6.69 Million
Q3 2023 Nov 14, 2023	SELL	$16.75 - $48.98 $2.98 Million - $8.7 Million	-177,619 Reduced 19.96%	712,424 $14.7 Million
Q2 2023 Aug 14, 2023	SELL	$40.65 - $59.54 $9.54 Million - $14 Million	-234,775 Reduced 20.87%	890,043 $41.8 Million
Q1 2023 May 15, 2023	BUY	$37.27 - $46.57 $1.56 Million - $1.95 Million	41,774 Added 3.86%	1,124,818 $47.2 Million

Q4 2022 Feb 14, 2023	SELL	$32.2 - $43.61 $335,942 - $454,983	-10,433 Reduced 0.95%	1,083,044 $41.3 Million
Q3 2022 Nov 14, 2022	BUY	$32.28 - $43.27 $10.4 Million - $13.9 Million	321,121 Added 41.58%	1,093,477 $42.8 Million
Q2 2022 Aug 15, 2022	SELL	$27.52 - $37.99 $1.19 Million - $1.64 Million	-43,265 Reduced 5.3%	772,356 $24.9 Million
Q1 2022 May 16, 2022	BUY	$30.71 - $45.71 $1.15 Million - $1.7 Million	37,299 Added 4.79%	815,621 $27 Million
Q4 2021 Feb 14, 2022	BUY	$37.06 - $47.11 $3.38 Million - $4.3 Million	91,290 Added 13.29%	778,322 $33.1 Million
Q3 2021 Nov 15, 2021	BUY	$40.26 - $57.37 $3.3 Million - $4.71 Million	82,091 Added 13.57%	687,032 $30.4 Million
Q2 2021 Aug 16, 2021	BUY	$54.88 - $79.29 $8.67 Million - $12.5 Million	157,987 Added 35.35%	604,941 $34.4 Million
Q1 2021 May 17, 2021	BUY	$70.65 - $96.76 $4.05 Million - $5.55 Million	57,320 Added 14.71%	446,954 $33.5 Million
Q4 2020 Feb 12, 2021	SELL	$58.41 - $89.06 $21,144 - $32,239	-362 Reduced 0.09%	389,634 $33.7 Million
Q3 2020 Nov 16, 2020	BUY	$41.13 - $62.45 $714,839 - $1.09 Million	17,380 Added 4.66%	389,996 $23.8 Million
Q2 2020 Aug 14, 2020	SELL	$25.95 - $43.15 $6.13 Million - $10.2 Million	-236,098 Reduced 38.79%	372,616 $15.5 Million
Q1 2020 May 15, 2020	BUY	$26.15 - $77.24 $7.03 Million - $20.8 Million	268,789 Added 79.07%	608,714 $17.4 Million
Q4 2019 Feb 14, 2020	SELL	$60.18 - $154.77 $6.92 Million - $17.8 Million	-114,910 Reduced 25.26%	339,925 $24.5 Million
Q3 2019 Nov 14, 2019	SELL	$140.29 - $189.96 $1.37 Million - $1.86 Million	-9,788 Reduced 2.11%	454,835 $63.8 Million
Q2 2019 Aug 14, 2019	BUY	$157.85 - $183.09 $16.9 Million - $19.6 Million	107,140 Added 29.97%	464,623 $85.1 Million
Q1 2019 May 15, 2019	BUY	$89.33 - $163.65 $9.44 Million - $17.3 Million	105,729 Added 42.0%	357,483 $56.9 Million
Q4 2018 Feb 14, 2019	SELL	$81.94 - $139.71 $6.4 Million - $10.9 Million	-78,083 Reduced 23.67%	251,754 $24.1 Million
Q3 2018 Nov 14, 2018	SELL	$138.11 - $169.04 $4.16 Million - $5.09 Million	-30,104 Reduced 8.36%	329,837 $46.3 Million
Q2 2018 Aug 14, 2018	BUY	$140.36 - $175.76 $7.39 Million - $9.25 Million	52,626 Added 17.12%	359,941 $56.3 Million
Q1 2018 May 15, 2018	BUY	$152.15 - $192.33 $19.5 Million - $24.7 Million	128,208 Added 71.58%	307,315 $49.5 Million
Q4 2017 Feb 12, 2018	BUY	$60.72 - $167.34 $7.06 Million - $19.5 Million	116,322 Added 185.27%	179,107 $29.5 Million
Q3 2017 Nov 07, 2017	BUY	$61.4 - $88.52 $3.85 Million - $5.56 Million	62,785	62,785 $3.91 Million

Others Institutions Holding SAGE

# of Institutions

222

Shares Held

52.7M

Call Options Held

207K

Put Options Held

191K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $631M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ameriprise Financial Inc with notifications on news.

Account

Ameriprise Financial Inc Sage Therapeutics, Inc. Transaction History